Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK). DermNet NZ Editor in Chief: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand, January 2018

What is guselkumab?

Guselkumab is a biologic treatment indicated for moderate to severe psoriasis.

The U.S. Food and Drug Administration (FDA) has approved guselkumab (Janssen Biotech, PA, USA; TREMFYA™) for the treatment of adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Guselkumab is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis.

Applications seeking approval of guselkumab in the European Union, Japan and other countries are currently under review.

What is guselkumab used for?

How does guselkumab work?

How is guselkumab given?

Pretreatment evaluation for tuberculosis and immunisation

Use in specific populations



Paediatric use

Geriatric use

Hepatic or renal impairment

Adverse effects of guselkumab

The most common adverse reactions (≥ 1% of patients) reported include:

Drug interactions with guselkumab

Contraindications to guzelkumab

Guzelkumab should not be used in patients that:

Guselkumab is promising for plaque psoriasis in phase 3 studies.

Related information

Email Newsletter

Would you like to receive our dermatology updates by email?


Submit your images

We're seeking high-quality photos of skin diseases.  


Machine diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter